The effect of systemic application of propolis on tongue damage and oral mucositis in rats exposed to radiation

2021 ◽  
Author(s):  
Gulhan Guler Avci ◽  
Ibrahim Erdim ◽  
Zeliha Cansel Ozmen ◽  
Fikret Gevrek ◽  
Sefa Colak ◽  
...  
Keyword(s):  
Oral Mucositis ◽  
Systemic Application

Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation

2020 ◽  
Vol 51 (3) ◽  
pp. 172-178
Author(s):  
Natalia Bartoszewicz ◽  
Krzysztof Czyżewski ◽  
Robert Dębski ◽  
Anna Krenska ◽  
Ewa Demidowicz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Clinical Course ◽  
Keratinocyte Growth Factor ◽  
Supportive Therapy ◽  
Primary Objective ◽  
Hematopoietic Cell ◽  
Unrelated Donor

AbstractIntroductionOral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.ObjectivesThe primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.Patients and methodsA total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.ResultsPatients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001).ConclusionsThe use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.

scholarly journals Severity of Oral Mucositis in Children following Chemotherapy and Radiotherapy and Its Implications at a Single Oncology Centre in Durango State, Mexico

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Ramón G. Carreón-Burciaga ◽  
Enrique Castañeda-Castaneira ◽  
Rogelio González-González ◽  
Nelly Molina-Frechero ◽  
Enrique Gaona ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Oral Mucositis ◽  
Preventive Treatment ◽  
World Health ◽  
Clinical Evaluations ◽  
Severity Scores ◽  
Therapeutic Protocols ◽  
Number Of Cycles ◽  
Oncology Centre ◽  
Health Organization

Background. Mucositis is an adverse effect of chemotherapy (QT) and/or radiotherapy (RT). The purpose of this study was to investigate the occurrence of oral mucositis in children undergoing cancer treatment. Methods. Fifty-one children with cancer who had received QT, RT, or both (QT-RT) underwent clinical evaluations; World Health Organization criteria were used to establish the degree and severity of mucositis. The correlations between the clinical data, type of cancer, and therapy were statistically analysed. Results. Mucositis was present in 88.23% of the patients; 57.78%, 7.78%, and 24.44% received QT, RT, and QT-RT, respectively. Severity scores of 1 and 2 were the most common; scores of 3-4 were observed in patients who received QT-RT or more than 7 treatment cycles. There was a significant association between mucositis, the type of treatment, and the number of cycles received (p<0.05). Conclusion. It is important to implement therapeutic protocols that help maintain excellent oral health and reduce the risk of oral mucositis. Stomatologists should be consulted to assess patients’ oral cavities and provide preventive treatment prior to QT and/or RT administration. It is important to integrate a stomatologist into the oncological working group to focus on preventing and managing oral mucositis.

scholarly journals Glutamine: Beneficial to prevent oral mucositis in Mexican children with acute lymphoblastic leukemia?

2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Miriam R. Caselin-García ◽  
Katja Stein ◽  
Miguel R. Kumazawa-Ichikawa ◽  
Oscar González-Ramella ◽  
Edgar M. Vásquez-Garibay ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Oral Mucositis ◽  
Lymphoblastic Leukemia ◽  
Mexican Children

Enhanced drug loading of in situ forming gels for oral mucositis pain control

2021 ◽  
Vol 595 ◽  
pp. 120225
Author(s):  
Tingting Li ◽  
Rajesh V. Lalla ◽  
Diane J. Burgess
Keyword(s):  
Oral Mucositis ◽  
Pain Control ◽  
Drug Loading ◽  
In Situ Forming

Intraoral versus extraoral photobiomodulation therapy in the prevention of oral mucositis in HSCT patients: a randomized, single-blind, controlled clinical trial

2021 ◽  
Author(s):  
Mariana Bitu Ramos-Pinto ◽  
Teresa Paula de Lima Gusmão ◽  
Jayr Schmidt-Filho ◽  
Graziella Chagas Jaguar ◽  
Manoela Domingues Martins ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Oral Mucositis ◽  
Photobiomodulation Therapy ◽  
Controlled Clinical Trial ◽  
Single Blind
Sign in / Sign up

Export Citation Format

Share Document